Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volasertib with DNX-FLA in Pediatric Relapsed/Refractory AML
NCT02722135Phase 1Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2016
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of volasertib in acute myeloid leukemia (AML), sponsored by Boehringer Ingelheim. Primary endpoint: Maximal Tolerated Dose or Recommended Dose at 4 weeks. Planned start Nov 2016; status: withdrawn.
02
Drugs
volasertib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02722135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02722135.